Showing results (2121-2130 of 2,629) with videos related to
Sort By:
Pageof 263
The Korean Journal of Internal Medicine|June 22, 2001
A case of malignant proliferating trichilemmoma of the scalp with multiple metastasesS B Bae, K K Lee, J S Kim, et al.European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|June 17, 2017
Comparison of the characteristics of Mycobacterium tuberculosis isolates from sputum and lung lesions in chronic tuberculosis patientsM-S Hong, Y Kim, E-J Cho, et al.Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|October 6, 2018
A J-shaped relation of BMI and stroke: Systematic review and dose-response meta-analysis of 4.43 million participantsX Liu, D Zhang, Y Liu, et al.British Journal of Cancer|February 21, 2018
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trialsShiraj Sen, Kenneth Hess, David S Hong, et al.Journal of the American Chemical Society|October 12, 2021
Implications of the Conformationally Flexible, Macrocyclic Structure of the First-Generation, Direct-Acting Anti-Viral Paritaprevir on Its Solid Form Complexity and Chameleonic BehaviorAhmad Y Sheikh, Alessandra Mattei, Rajni Miglani Bhardwaj, et al.International Journal of Cancer|January 26, 2019
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumorsIgnacio Garrido-Laguna, Ian Krop, Howard A Burris, et al.Clinical Genitourinary Cancer|December 25, 2013
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinomaDavid S Hong, Michael S Gordon, Wolfram E Samlowski, et al.Oncotarget|June 11, 2014
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathwayJennifer J Wheler, Stacy L Moulder, Aung Naing, et al.Oncotarget|March 3, 2016
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimusXiaochun Liu, Susan Kambrick, Siqing Fu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2021
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR InhibitorDavid S Hong, Kathleen N Moore, Johanna C Bendell, et al.Pageof 263